Objective To determine the safety of an injectable levetiracetam-concentrated solution(LEV-iv)during the perioperative period in patients with epilepsy who underwent elective surgery.Methods Patients with epilepsy who were admitted to the Neurosurgery Department or Department of Functional Neurology in seven hospitals for surgical treatment of epilepsy were included.The patients were 4-80 years of age,diag-nosed with drug-resistant epilepsy,and met the criteria for surgery.LEV-iv was administered the day after surgery;the specific dose was determined based on age and body weight.Drug-related adverse reactions during LEV-iv were analyzed,the laboratory-related indicators were detected,the proportion of patients with epilep-tic seizure was determined,and the type and frequency of epileptic seizures were analyzed.Results All pa-tients successfully completed the planned surgery.The duration of LEV-iv administration during the perioper-ative period was≥3 days;the median duration was 6 days.During the medication period,3 patients(1.97%)had drug-related adverse reactions.The main manifestations of drug-related adverse reactions were drowsi-ness,anxiety,and irritability in 1 patient,and dizziness and headaches in 2 patients.None of the adverse reactions required specific treatment and gradually improved.No drug-related adverse reactions were ob-served in other patients.The following laboratory abnormalities were recorded:electrolyte disturbances,9 pa-tients;elevated white blood cell counts,7 patients;elevated neutrophils,4 patients;coagulopathy,4 pa-tients;elevated transaminases,3 patients;and elevated glutamyltransferase,3 patients.Indeed,the abnormal laboratory indices were thought to be related to the routine application of dehydrating agents and anticoagu-lants after surgery and the occurrence of stress inflammatory reactions.Four patients(2.63%)had seizures,all of which were partial seizures.Two of the patients had seizures on the day of medication(1 time/day)and 2 patients had seizures on the day of medication(3 and 4 times/day).Conclusion LEV-iv is shown to have enhanced safety during perioperative use in patients with epilepsy,and can effectively control perioperative seizures.
维普
万方数据